Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

More on GLP-1 and incretin signalling

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• Retatrutide reduces weight and pain in adults with obesity

  The New England Journal of Medicine · 4 Oct 2026

• A triple-target drug cut body weight by up to 19.7% in a trial

  Cell Metabolism · 8 Oct 2026